tbuckley/cabot-search huggingface dataset:
Characterization of WU-CART-007, an Allogeneic CD7-Targeted CAR-T Cell Therapy for T-Cell Malignancies
Authors: Tom Leedom, Alexander S. Hamil, Somayeh Pouyanfard, Jennifer Govero, Rachel Langland, Anna Ballard, Liz Schwarzkopf, Andrew Martens, Andrew Espenschied, Pooja Vinay, Michael James, Nitin Mahajan, David H Spencer, Kenneth M Chrobak, Matthew L Cooper, Ayman Kabakibi
Journal: Blood (2021)
Abstract 10755: Network Meta-Analysis of Randomized Controlled Trials of Eicosapentaenoic Acid for Cardiovascular Events Reduction
Authors: Yujiro Yokoyama, Toshiki Kuno, Sae Morita, Hisato Takagi, Alexandros Briasoulis, Azeem Latib, Sean Heffron, Sripal Bangalore
Journal: Circulation (2021)

Background: Randomized clinical trials (RCTs) investigating the impact of omega-3-fatty acid supplementation on cardiovascular events have largely shown no benefit. A recent RCT suggested benefit from an eicosapentaenoic acid (EPA)-only supplement. However, there is debate about the benign nature of the placebo in this trial. Methods: MEDLINE and EMBASE were searched through May, 2021 to identify RCTs that investigated cardiovascular outcomes with omega-3-fatty acid formulations (EPA, decosahexanoic acid (DHA) or the combination) versus placebo or standard care of controls. Outcomes of interest were cardiovascular death, myocardial infarction, stroke, coronary revascularization, and all-cause death. Results: Our analysis included 17 RCTs that enrolled a total of 141,009 patients randomized to EPA (n =13,655), EPA+DHA (n =56,908), mineral oil placebo (n =5,338), corn oil placebo (n =8,876), olive oil placebo (n =41,009) and controls (no placebo oil; n =15,223). Rates of cardiovascular death, myocardial infarction and stroke were significantly lower in those receiving EPA compared to those receiving mineral oil, but were not different from rates in those receiving other oils or standard of care controls. Rates of coronary revascularization were significantly lower in those receiving EPA than in those receiving either EPA+DHA, mineral oil, corn oil, or olive oil placebo, but not standard of care controls. All-cause death was similar among all groups. Conclusion: Our analyses demonstrate that although EPA supplementation lowers risk of coronary revascularization more than other oils, there is no benefit relative to standard of care. Further, EPA reduces the risk of cardiovascular events only in comparison to mineral oil and not when compared with other placebo oils or to standard of care. Any benefit of EPA-only supplementation in improving cardiovascular outcomes is not currently generalizable outside of select studies incorporating mineral oil placebo.
Abstract 10012: The Relationship Between Mitral Valve Regurgitation and Left Atrial Enlargement on the Risk of Stroke and Systemic Embolism in Japanese Atrial Fibrillation Patients: The Fushimi Af Registry
Authors: KOSUKE DOI, Kenjiro Ishigami, Syuhei Ikeda, Yasuhiro Hamatani, Yuya Ide, Akiko Fujino, MITSURU ISHII, Moritake Iguchi, Hisashi Ogawa, Nobutoyo Masunaga, Hiromichi Wada, Koji Hasegawa, Mitsuru Abe, Masaharu Akao
Journal: Circulation (2021)

Background: We previously reported that left atrial enlargement (LAE) was an independent predictor of stroke/systemic embolism (SE) in Japanese atrial fibrillation (AF) patients. Mitral regurgitation (MR) likely accompanies LAE; it sometimes causes LAE and conversely LAE can cause secondary MR. However, the relationship between MR and LAE on the risk of stroke/SE is unknown. Purpose: The aim of this study is to investigate the impact of LAE on stroke/SE in AF patients with or without MR. Method: The Fushimi AF Registry is a community-based prospective survey of AF patients in Fushimi-ku, Kyoto, which is a typical urban district of Japan. We started to enroll patients from March 2011, and follow-up data were available for 4,472 patients by the end of October 2020. In the entire cohort, echocardiography data were available for 3,622 patients. 131 AF patients with rheumatic mitral stenosis or prosthetic valve and 63 patients without data of left atrial diameter (LAD) were excluded. We divided eligible 3,428 patients in MR group (n=393) and non-MR group (n=3,035). We compared clinical characteristics and rates of stroke/SE between patients with LAE (LAD &amp;gt; 45mm) and without LAE (Non-LAE) in each group. Result: In both MR and non-MR groups, patients with LAE were, as compared with non-LAE, more in body weight, more often persistent/permanent type, more likely to have chronic kidney disease. LAE group was older, more likely have heart failure, hypertension, diabetes mellitus and more often received oral anticoagulant in non-MR group, but not in MR group. During the median follow-up of 1,804 days, the incidence rate of stroke/SE was higher in LAE than non-LAE in non-MR group (2.13 vs. 1.08 per 100 person-years, respectively, log rank p&amp;lt;0.001), but it was comparable between LAE and non-LAE groups in MR group (1.23 vs. 1.82 per 100 person-years, respectively, log rank p=0.41). Conclusion: The incidence rate of stroke/SE was higher in LAE than non-LAE in non-MR group, but not in MR group.
Abstract 9551: Presence of Disabilities is Associated With Reproductive Health Counseling, Concerns, and Experiences and Marital History Among Women With Congenital Heart Defects, 2016-2019
Authors: Sherry L Farr, Scott E Klewer, Wendy N Nembhard, Karrie F Downing, Maureen Galindo, Elijah H Bolin, Argelia Benavides, Ashley Judge, Matthew Oster
Journal: Circulation (2021)

Most females with congenital heart defects (CHD) will reach reproductive age. Our objective was to examine whether presence of disabilities is associated with reproductive health counseling, concerns, and experiences among women with CHD. Methods: We used 2016-2019 population-based data from the Congenital Heart Survey To Recognize Outcomes, Needs, and well-beinG (CH STRONG) among women ages 19 to 38 years with CHD born in Arkansas, Arizona, and Atlanta, Georgia. We examined contraceptive and pregnancy counseling, pregnancy concerns and experiences, and marital history by disability status. Disability was based on six validated questions on vision, hearing, mobility, cognition, self-care, and independent living. Multivariable Poisson regression was used to examine adjusted prevalence ratios (aPR) between reporting ≥ 1 disability and each outcome, adjusted for CHD severity, age, race/ethnicity, place of birth, and insurance type. Results: Of 783 survey respondents with complete data (88% of all respondents), 41.9% were 25-30 years of age, 66.8% were non-Hispanic White, and 41.5% reported ≥1 disability. Women with CHD and disabilities were more likely than women without disabilities to receive clinician counseling on safe contraceptive methods (aPR=1.3) and on avoiding pregnancy because of their CHD (aPR=2.3). They were also more likely to report concern about their ability to have children (aPR=1.2) and having delayed or avoided pregnancy because of their CHD (aPR=2.2). They were less likely to have ever been pregnant (aPR=0.8) or married (aPR=0.7). Associations held across specific disability types and after excluding 71 women with known chromosomal anomalies. Conclusions: Among women with CHD, those with disabilities may be more likely to receive clinician advice to avoid pregnancy and less likely to ever have been pregnant. Evidence-based information may improve services and help women with CHD and disabilities meet their reproductive health goals.
Covid-19: surging demand for some arthritis drugs
Authors: Joanna M Ledingham, Elizabeth MacPhie, Ailsa Bosworth
Journal: BMJ (2021)

Over the past 18 months, shortages have emerged for several medications used to control inflammatory rheumatological diseases, the highest profile of which is tocilizumab.Early in the pandemic, there was considerable interest in hydroxychloroquine-a drug for rheumatoid arthritis and systemic lupus erythematosus-as a possible treatment for covid-19. 1A surge in demand led to concerns about shortages and a warning from the US Food and Drug Administration in April 2020. 2 Demand abated after studies showed it was ineffective in preventing and treating covid-19.
Machine-Learning Model for Resistance/Relapse Prediction in Immune Thrombocytopenia Using Gut Microbiota and Function Signatures
Authors: Feng-Qi Liu, Qi Chen, Qingyuan Qu, Xueyan Sun, Qiu-Sha Huang, Yun He, Xiaolu Zhu, Chencong Wang, Hai-Xia Fu, Yue-Ying Li, Qian-fei Wang, Kai-Yan Liu, Xiao-Hui Zhang
Journal: Blood (2021)
The Echelon-2 Trial: 5-Year Exploratory Subgroup Analyses of a Randomized, Double-Blind, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Vs CHOP in Frontline Treatment of Pts with CD30-Positive Peripheral T-Cell Lymphoma
Authors: Steven M. Horwitz, Kerry J. Savage, Tim Illidge, Swaminathan P Iyer, Ranjana Advani, Andrei R Shustov, Nancy L. Bartlett, Barbara Pro, Eric D Jacobsen, Raphael Koch, Domingo Domenech Eva, Michelle A. Fanale, Keenan Fenton, Frank Campana, Cassie Dong, Lorenz Truemper
Journal: Blood (2021)
Telephone, video, equity and access in virtual care
Authors: Tyla Thomas-Jacques, Trevor Jamieson, James Shaw
Journal: npj Digital Medicine (2021)

Current public health measures catalyzed a large shift to virtual care, resulting in a great uptake in telephone and video-enabled care. While pre-pandemic public healthcare funding rarely covered the telephone as a reimbursable care delivery model, it has proven a crucial offering for many populations. As the new standard of virtual service delivery is being solidified, simple technological solutions that provide access to care must continue to be supported. This paper explores an important consequence of relying on complex technologies as the new standard of virtual care: the risk of exacerbating health disparities by enabling a deeper digital divide for marginalized populations.
Abstract 9445: Gender Disparities in Statin Prescriptions Following Acute Coronary Syndrome
Authors: Sydney Emerson, Maxwell Ambrosino, Patricia Hernandez, Douglas Jacoby
Journal: Circulation (2021)

Introduction: Initiation of high intensity statin therapy for patients following acute coronary syndrome (ACS) is well-established secondary prevention. Females with coronary artery disease have historically been associated with lower rates of goal directed medical therapy. Hypothesis: Disparities in statin prescriptions and targeted reductions in LDL levels exist between genders. Methods: A cross-sectional study was employed across the University of Pennsylvania Health System from 2018 to 2019. Electronic medical records were queried for all admitted patients diagnosed with ACS. Data was collected for age, gender, race, and lipid profiles on discharge and up to 1-year post-discharge. Results: The study population included 3386 patients of which 2264 (66.8%) were male and 1122 (33.14%) were female. At discharge after ACS event, 81.1% of males were on GDLT compared to only 71.6% females. Further, at post-discharge follow-up 65.1% males were still on GDLT compared to 58.3% of females. Rates of goal LDL &lt; 70 mg/dL at post-discharge was 55.5% (602/1085) for males compared to 41.2% (226/548) for females. At this time, ezetimibe prescription rates for males was 7.4% and females was 6.9%. At post-discharge, interestingly, PCSK9-inhibitor prescription rates were 2.9% for females compared to 1.9% for males. Conclusions: Overall, male patients had higher rates of statin prescriptions than female patients on hospital discharge and at post-discharge follow-up. Further, less than half of female patients had LDL &lt; 70 mg/dL at follow-up. Therefore, over half of female patients should be on further lipid lowering therapies. Yet, less than 7% of females are prescribed ezetimibe and only 2.9% are prescribed PCSK9-inhibitors. Further understanding of discrepancies in statin and non-statin prescription rates for female patients are warranted to allow for appropriate secondary ACS prevention.
Myelodysplastic Syndromes (MDS) Presenting with Isolated Thrombocytopenia: Characteristics, Outcomes, and Clinical Presentation Differences from Immune Thrombocytopenic Purpura (ITP)
Authors: Konstantinos Liapis, Vasileios Papadopoulos, George Vrachiolias, Emily Stavroulaki, Christina Misidou, Alexandra Kourakli, Athanasios Galanopoulos, Menelaos Konstantinos Papoutselis, Sotirios Papageorgiou, Panagiotis T Diamantopoulos, Vassiliki Pappa, Nora-Athina Viniou, Dimitris Tsokanas, Theodoros P. Vassilakopoulos, Eleftheria Hatzimichael, Epameinondas Koumpis, Konstantina Papathanasiou, Eleni Bouronikou, Maria Ximeri, Charalampos Pontikoglou, Aikaterini Megalakaki, Panagiotis Zikos, Panayiotis Panayiotidis, Maria Dimou, Stamatis J. Karakatsanis, Anna Vardi, Flora Kontopidou, Nikolaos Charchalakis, Ioannis Adamopoulos, Helen A. Papadaki, Argiris Symeonidis, Kotsianidis Ioannis
Journal: Blood (2021)
Echocardiographic and Doppler Aspects of Chronic Pulmonary Heart. About 11 cases
Authors: Bani Am
Journal: Clinical Cardiology and Cardiovascular Interventions (2021)

Pulmonary chronic heart (CPC) is an enlargement associated or not with dilation of the right ventricle. Objective: To recall the echocardiographic-Doppler aspects essential for the screening of pulmonary chronic heart. Patients and method: Retrospective study carried out between January 2009 and April 2019 interesting the cases of pulmonary chronic heart. Results: out of 124 cases of pulmonary chronic heart, 11 cases were included. These were four men and 7 women with a mean age of 63 ± 19 years (range: 20-84 years). The radiological and electrical semiology of pulmonary chronic heart was found, lacking specificity and sensitivity. Dilation of the right heart chambers, dyskinesia of the interventricular septum and hypertrophy of the free wall of the right ventricle ˃ 5 mm were observed. The mean maximum velocity of tricuspid insufficiency on continuous Doppler was 4.6 ± 1.32 ms / s (Extremes: 3.59-7.58 m / s) and the mean dilation of the inferior vena cava was 23.2 ± 3.9mm (Extreme: 21.2-27mm). Conclusion: CPC is uncommon and predominant in women. The EKG and chest X-ray are first-line exams without sensitivity or specificity. Screening for CPC is based on echocardiographic-Doppler criteria. The right cardiac catheterization remains the key examination.
Abstract 9313: Clinician Training, Implicit Bias, and Self-Efficacy in Treating African American Patients: A Substudy of the HYpertension and VALUEs Trial
Authors: Vy A Pham, Irene Blair, Laura Helmkamp, Julie A Maertens, Rebecca Hanratty, Suma Vupputuri, John Steiner, Edward P Havranek, Miriam L Dickinson, Stacie L Daugherty
Journal: Circulation (2021)

Background: Implicit bias among clinicians is believed to contribute to health disparities. Clinicians have racial biases comparable to others in society, leading to calls for trainings in cultural awareness. However, whether such trainings improve clinician self-efficacy or reduce bias is not well known. We assessed the relationships between prior cultural awareness training, perceived efficacy in caring for African American patients, and implicit race bias. Methods: As part of a larger trial, a sample of primary care clinicians (PCPs) completed a race implicit association test (IAT) and survey regarding prior training in cultural awareness, and perceived efficacy in caring for African American patients (i.e., preparation to care for, and skill in developing positive relationships and overcoming bias). IAT d-scores measure racial implicit bias with scores &gt;+0.15 indicating “pro-White” race bias, scores &lt;-0.15 indicating “pro-Black”race bias and scores between -0.15 to +0.15 indicating “no bias”. Groups were compared using chi-squared tests for categorical variables and t-tests for continuous variables Results: Among 137 PCPs (63% female, 61% White, 51% ≤10 years in practice), 65% showed implicit pro-White race bias (mean IAT d-score = 0.34 (SD 0.44)) and 79% reported prior training in cultural awareness. Though 67% of participants felt “very prepared” to care for and 59% felt “very skilled” in developing a positive relationship with African American patients, only 26% felt “very skilled” in overcoming implicit racial bias. Prior training in cultural awareness was not associated with perceived efficacy in caring for African American patients (all p &gt;0.05). IAT scores were similar between clinicians who had training in cultural awareness and those without prior training (Mean(SD)=0.32(0.47) vs. 0.42(0.35), p=0.32). Conclusions: In this sample of PCPs, prior cultural awareness training was not associated with either implicit bias or preceived efficacy in caring for African American patients. This study suggests that cultural awareness trainings may need to be further developed and expanded to target implicit bias and improve clinician self-efficacy.
Combination of Three Unique Anti-Tumor Modalities Engineered into iPSC-Derived T Cells Demonstrate a Synergistic Effect in Overcoming Tumor Heterogeneity and Cancer Escape
Authors: Bi-Huei Yang, Yu-Sheng Eason Lin, Soheila Shirinbak, Wen-I Yeh, Mochtar Pribadi, Hui-Yi Chu, Alma Gutierrez, Amit Mehta, Earl Avramis, Roseanna Petrovic, Benjamin Whitlock, Jason ORourke, Sjoukje van der Stegen, Tom Lee, Alec Witty, Eigen Peralta, Martin Hosking, Chia-Wei Chang, Bahram Valamehr
Journal: Blood (2021)
Mortality and Evolution Between Community and Hospital-Acquired COVID-AKI (CA-AKI and HA-AKI)
Authors: Jonathan Chavez, Fidel Ramos Avellaneda, Andrea Luna, Marcela Plascencia Cruz, Alejandro Martínez Gallardo González, José D. González Barajas, Frida Margarita d. Méndez, Guillermo Garcia-Garcia
Journal: Journal of the American Society of Nephrology (2021)

Background: Differences between HA-AKI and CA-AKI are not well stablished Methods: Retrospective cohort. We included 877 patients hospitalized with COVID at two hospitals in Mexico. Primary outcome was all-cause mortality at 28 days compared between COVID with CA-AKI and HA-AKI. Secondary outcomes included the need for KRT, and risk factors associated with the development of CA-AKI and HA-AKI. Results: A total 33.7% developed AKI. CA-AKI occurred in 59.9% and HA-AKI occurred in 40.1%. Patients with CA-AKI had more comorbidities than those with HAAKI. Patients' survival with CA-AKI it was 75.4%, and with HA-AKI 69.6%. Age > 60 years (OR 1.12), COVID severity (OR 1.09), mechanical ventilator (OR 1.67), and HAAKI 3 (OR 1.16) increase mortality. The presence of CKD (OR 1.48), serum lymphocytes < 1000 μL (OR 1.03), the need for mechanical ventilator (OR 1.06), and CA-AKI stage 3 (OR 1.37) were the only variables associated with a KRT start. Conclusions: We found that COVID complicated by CA-AKI have more comorbidities and worse biochemical parameters than HA-AKI patients, but despite these differences, their probability of dying is similar.
Differential Prognostic Impact of <i>IDH1</i> and <i> IDH2</i> Mutations in Chronic Myelomonocytic Leukemia
Authors: Connor M. Walsh, Anthony Hunter, Terra Lasho, Christy Finke, Rami S. Komrokji, Mithun V. Shah, Ayalew Tefferi, Abhishek A. Mangaonkar, Matthew T Howard, Naseema Gangat, Aref Al-Kali, Najla Al Ali, Eric Padron, Mrinal M. Patnaik
Journal: Blood (2021)
Six-Year Results from the Phase 3 Randomized Study Relevance Show Similar Outcomes for Previously Untreated Follicular Lymphoma Patients Receiving Lenalidomide Plus Rituximab (R 2) Versus Rituximab-Chemotherapy Followed By Rituximab Maintenance
Authors: Franck Morschhauser, Loretta Nastoupil, Pierre Feugier, Jean Marc Schiano De Colella, Hervé Tilly, M. Lia Palomba, Emmanuel Bachy, Christophe Fruchart, Edward Libby, Rene-Olivier Casasnovas, Ian W. Flinn, Corinne Haioun, Herve Maisonneuve, Loic Ysebaert, Nancy L. Bartlett, Kamal Bouabdallah, Pauline Brice, Vincent Ribrag, Steven Le Gouill, Nicolas Daguindau, Vincent Delwail, Gian-Matteo Pica, Alejandro Martin Garcia-Sancho, Armando Lopez-Guillermo, Jean-Francois Larouche, Kiyoshi Ando, Gomes da Silva Maria, Marc André, Ka Lung Wu, Laurie H. Sehn, Koji Izutsu, Guillaume Cartron, Argyrios Gkasiamis, Russell Crowe, Luc Xerri, Nathan H. Fowler, Gilles Salles
Journal: Blood (2021)
Identification of Patient-Specific Anti-Apoptotic Molecules As Therapeutic Targets in Poor Prognosis Acute Lymphoblastic Leukemia (ALL)
Authors: Ryo Nakagawa, Yoriko Saito, Shinsuke Takagi, Sadaaki Takata, Hanae Amitani, Mikiko Endo, Naoyuki Uchida, Yukihide Momozawa, Shuichi Taniguchi, Hideo Harigae, Fumihiko Ishikawa
Journal: Blood (2021)
Association of the CYP39A1 G204E Genetic Variant with Increased Risk of Glaucoma and Blindness in Patients with Exfoliation Syndrome
Authors: Katharina Bell, Mineo Ozaki, Kazuhiko Mori, Takanori Mizoguchi, Satoko Nakano, Natalia Porporato, Yoko Ikeda, Etsuo Chihara, Kenji Inoue, Shinichi Manabe, Ken Hayashi, Tomomi Higashide, Ryuichi Ideta, Kana Tokumo, Yoshiaki Kiuchi, Masakazu Nakano, Morio Ueno, Shigeru Kinoshita, Kei Tashiro, Chie Sotozono, Masaru Inatani, Kazuhisa Sugiyama, Toshiaki Kubota, Zheng Li, Zhenxun Wang, Chiea Chuen Khor, Tin Aung
Journal: Ophthalmology (2021)
Selinexor in Combination with R-GDP for Patients with Relapsed/Refractory B-Cell Lymphoma: Results of the Selinda Phase Ib Lysa Study
Authors: Marie Maerevoet, Olivier Casasnovas, Guillaume Cartron, Franck Morschhauser, Catherine Thieblemont, Kamal Bouabdallah, Pierre Feugier, Vanessa Szablewski, Stephanie Becker, Hervé Tilly
Journal: Blood (2021)
Novel Single Agents Are Equivalent to Conventional Chemotherapy Inpatients with Relapsed and Refractory Mature T-Cell Lymphomas: A Meta-Analysis
Authors: Nazila Shafagati, Robert N. Stuver, Leora Boussi, Min Jung Koh, Allison Park, Paul Bain, Francine M. Foss, Changyu Shen, Salvia Jain
Journal: Blood (2021)
Integrative Multi-Omics Landscape of Non-Structural Protein 3 of Severe Acute Respiratory Syndrome Coronaviruses
Authors: Ruona Shi, Zhenhuan Feng, Xiaofei Zhang
Journal: Genomics Proteomics & Bioinformatics (2021)

Abstract The coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is currently a global pandemic. Extensive investigations have been performed to study the clinical and cellular effects of SARS-CoV-2 infection. Mass spectrometry-based proteomics studies have revealed the cellular changes due to the infection and identified a plethora of interactors for all SARS-CoV-2 components, except for the longest non-structural protein 3 (NSP3). Here, we expressed the full-length NSP3 proteins of SARS-CoV and SARS-CoV-2 to investigate their unique and shared functions using multi-omics methods. We conducted interactome, phosphoproteome, ubiquitylome, transcriptome, and proteome analyses of NSP3-expressing cells. We found that NSP3 plays essential roles in cellular functions such as RNA metabolism and immune response (e.g., NF-κB signal transduction). Interestingly, we showed that SARS-CoV-2 NSP3 has both endoplasmic reticulum and mitochondrial localizations. In addition, SARS-CoV-2 NSP3 is more closely related to mitochondrial ribosomal proteins, whereas SARS-CoV NSP3 is related to the cytosolic ribosomal proteins. In summary, our integrative multi-omics study of NSP3 improves the understanding of the functions of NSP3 and offers potential targets for the development of anti-SARS strategies.